{
    "2019-01-29": [
        [
            {
                "time": "2018-03-15",
                "original_text": "Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?",
                "features": {
                    "keywords": [
                        "VanEck",
                        "Vectors",
                        "Pharmaceutical",
                        "ETF",
                        "PPH"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-04-22",
                "original_text": "Pfizer and Lilly Announce Top-Line Results From Second Phase 3 Study of Tanezumab in Osteoarthritis Pain",
                "features": {
                    "keywords": [
                        "Pfizer",
                        "Lilly",
                        "Tanezumab",
                        "Phase 3",
                        "Osteoarthritis",
                        "Pain"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2019-04-22",
                "original_text": "Pfizer, Lilly Announce Results From Phase 3 Study Of Tanezumab In OA Pain",
                "features": {
                    "keywords": [
                        "Pfizer",
                        "Lilly",
                        "Tanezumab",
                        "Phase 3",
                        "OA",
                        "Pain"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-02-05",
                "original_text": "Dr. Reddy's (RDY) to Report Q3 Earnings: What's in Store?",
                "features": {
                    "keywords": [
                        "Dr. Reddy's",
                        "RDY",
                        "Q3",
                        "Earnings"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}